Skip to main content
Premium Trial:

Request an Annual Quote

Euroimmun to Sell Oncgnostics Cervical Cancer Test in Certain Parts of Europe

NEW YORK – Euroimmun will sell Oncgnostics'cervical cancer test in parts of Europe under an agreement announced on Thursday.

Euroimmun, a PerkinElmer subsidiary, will sell the GynTect test in Portugal, Italy, Turkey, and Poland. Financial and other terms of the deal were not disclosed.

Germany-based Oncgnostics added that it expects the test to be approved by regulators in Canada and to be sold there by the end of the year.

The PCR-based test detects DNA methylation and is performed in Oncgnostics laboratory with results available in a few days, according to the firm's website.

Euroimmun offers its own EuroArray HPV, a molecular test for detecting and genotyping human papillomavirus, and with the addition of GynTect, it "now has a complete package for cervical cancer diagnosis," Euroimmun CEO Wolfgang Schlumberger said in a statement.

The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.